The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II, double-blind, randomized study of salvage radiation therapy (SRT) plus enzalutamide or placebo for high-risk PSA-recurrent prostate cancer after radical prostatectomy: The SALV-ENZA Trial.
 
Phuoc T. Tran
Honoraria - Reflexion Medical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Dendreon; GenomeDx; Janssen; Myovant Sciences; Noxopharm; Reflexion Medical; Reflexion Medical; Regeneron
Research Funding - Astellas Pharma (Inst); Bayer Health (Inst); Reflexion Medical (Inst)
Patents, Royalties, Other Intellectual Property - Compounds and Methods of Use in Ablative Radiotherapy. Patent filed 3/9/2012. PCT/US2012/028475. PCT/WO/2012/122471.
Travel, Accommodations, Expenses - Reflexion Medical
 
Kathryn Lowe
No Relationships to Disclose
 
Hao Wang
No Relationships to Disclose
 
Hua-Ling Tsai
No Relationships to Disclose
 
Daniel Y. Song
No Relationships to Disclose
 
Arthur Hung
Research Funding - Janssen Oncology (Inst)
 
Jason W.D. Hearn
Consulting or Advisory Role - The Dedham Group
 
Tamara L. Lotan
No Relationships to Disclose
 
Channing Judith Paller
Consulting or Advisory Role - Dendreon; Exelixis; Omnitura
Research Funding - Lilly (Inst)
 
Mark Christopher Markowski
Honoraria - Clovis Oncology; Exelixis
 
Samuel R. Denmeade
Research Funding - Astellas Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Patent licensed to Pfizer receive patent maintenance fees
 
Michael Anthony Carducci
Consulting or Advisory Role - Exelixis; Foundation Medicine; Pfizer; Roche/Genentech
Research Funding - Arcus Biosciences (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); pfizer (Inst)
 
Mario A. Eisenberger
Leadership - Veru
Stock and Other Ownership Interests - Veru
Honoraria - Bayer; Bristol-Myers Squibb; Merck Sharp & Dohme; Seagen
Travel, Accommodations, Expenses - Veru
 
Matthew Orton
No Relationships to Disclose
 
Curtiland Deville
No Relationships to Disclose
 
Stanley L. Liauw
No Relationships to Disclose
 
Elisabeth I. Heath
Honoraria - Bayer; Sanofi; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Sanofi
Speakers' Bureau - Sanofi
Research Funding - Agensys (Inst); AIQ Solutions (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calibr (Inst); Caris Life Sciences (Inst); Celgene (Inst); Celldex (Inst); Champions Oncology (Inst); Corcept Therapeutics (Inst); Curemeta (Inst); Daiichi Sankyo Inc. (Inst); Dendreon (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); Esanik (Inst); Five Prime Therapeutics (Inst); Fortis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Inovio Pharmaceuticals (Inst); Janssen Research & Development (Inst); Medivation (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Modra Pharmaceuticals (Inst); Novartis (Inst); Oncolys BioPharma (Inst); Pellficure (Inst); Peloton Therapeutics (Inst); Pharmacyclics (Inst); Plexxikon (Inst); Seagen (Inst); Synta (Inst); Tokai Pharmaceuticals (Inst); Zenith Epigenetics (Inst); Zenith Epigenetics (Inst)
Other Relationship - Caris Centers of Excellence
 
Neil B Desai
Consulting or Advisory Role - Boston Scientific
Speakers' Bureau - Ultimate Medical Academy
Research Funding - Boston Scientific
Travel, Accommodations, Expenses - Boston Scientific
(OPTIONAL) Uncompensated Relationships - Bayer; Janssen Oncology
 
Tomasz M. Beer
Stock and Other Ownership Interests - Arvinas; Salarius Pharmaceuticals
Consulting or Advisory Role - Abbvie; Amgen; Arvinas; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Constellation Pharmaceuticals; Dantari Pharmaceuticals; GlaxoSmithKline; GRAIL; Janssen; Myovant Sciences; Pfizer; Sanofi; Sapience Therapeutics
Research Funding - Alliance Foundation Trials (Inst); Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Corcept Therapeutics (Inst); Endocyte (Inst); Freenome (Inst); GRAIL (Inst); Harpoon Therapeutics (Inst); Janssen Research & Development (Inst); Medivation (Inst); Sotio (Inst); Theraclone Sciences (Inst); Zenith Epigenetics (Inst)
 
Emmanuel S. Antonarakis
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb/Celgene; Celgene; Clovis Oncology; Constellation Pharmaceuticals; Curium Pharma; Dendreon; ESSA; Exact Sciences; Foundation Medicine; GlaxoSmithKline; InVitae; ISMAR Health Care; Janssen Biotech; Lilly; Medivation; Merck; Sanofi; Tempus
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb/Celgene; Clovis Oncology; Constellation Pharmaceuticals; Curium Pharma; Dendreon; ESSA; Exact Sciences; Foundation Medicine; GlaxoSmithKline; InVitae; ISMAR Health Care; Janssen Biotech; Lilly; Medivation; Merck; Sanofi; Tempus
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Celgene; Clovis Oncology; Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi